Cancer clinical trials in the region Île-de-France

726 currently recruiting clinical trials
Region Île-de-France

Phase 1 / Phase 2 Endometrial cancer #NCT04590326
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Regeneron Pharmaceuticals
Phase 1 / Phase 2 Endometrial cancer #NCT03564340 #2024-510783-23-00
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Regeneron Pharmaceuticals
Phase 1 / Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT03564340 #2024-510783-23-00
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Regeneron Pharmaceuticals
Phase 1 / Phase 2 Prostate cancer #NCT07206056 #2025-521880-10-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Novartis
Phase 1 / Phase 2 Lymphoma #NCT05607420 #2022-501607-27-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma Primary mediastinal lymphoma Mantel cell lymphoma Follicular lymphoma Marginal zone lymphoma MALT lymphoma Indolent transformed lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
2 3 or more
Required previous treatments
Chemotherapy Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive Car-T
4 recruiting sites
Cellectis SA
Phase 1 / Phase 2 Lymphoma #NCT05607420 #2022-501607-27-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma Follicular lymphoma Indolent transformed lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
2 3 or more
Required previous treatments
Chemotherapy Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive Car-T
4 recruiting sites
Cellectis SA
Phase 1 / Phase 2 Lymphoma #NCT06495723 #2023-509648-88-00
Required histologic types
T cell lymphoma
Required histologic sub types
Peripheral T cell lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Chemotherapy
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Xenothera SAS
Phase 1 / Phase 2 Lung cancer #NCT06362252 #2023-509629-36-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
8 recruiting sites
Daiichi Sankyo
Phase 1 / Phase 2 Lymphoma CLL & Richter's syndrome #NCT06542250 #2024-511099-34-00
Required histologic types
B cell lymphoma CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Large B cell lymphoma Mantel cell lymphoma Follicular lymphoma Lymphocytic lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
2 recruiting sites
AstraZeneca
Phase 1 / Phase 2 Liver and bile duct cancer #NCT04524871 #2023-506611-17-00
Required histologic sub types
Hepatocellular carcinoma
Required disease stage
Locally Advanced Metastatic
Required liver status
Unhealthy
Required Child-Pugh scores
A
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
2 recruiting sites
Hoffmann-La Roche